By demonstrating an empagliflozin (Empa)-mediated inhibition of basal as well as IL-1β-mediated MCP-1/CCL2 and ET-1 expression under normoglycemic conditions, we present novel evidence for the interference of SGLT2 inhibition with tubular inflammatory response mechanisms that could convey SGLT2i-mediated renoprotection in normoglycemic CKD patients. This evidence concerns the gene CCL2 and chronic kidney disease.